Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Amivantamab-VMJM in Glioblastoma Multiforme: NCT06632236 Clinical Landscape Report 2026
15 October 2026
NCT06632236 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Levocetirizine Hydrochloride in Triple Negative Breast Cancer: NCT06632405 Clinical Landscape Report 2026
15 October 2026
NCT06632405 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab biosimilar(Biocad) in Melanoma, Cutaneous Malignant: NCT06640530 Clinical Landscape Report 2026
15 October 2026
NCT06640530 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Folate receptor alpha vaccine(Mayo Clinic) in Primary Peritoneal High-Grade Serous Adenocarcinoma: NCT06639074 Clinical Landscape Report 2026
15 October 2026
NCT06639074 clinical landscape for Primary Peritoneal High-Grade Serous Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
Dupilumab in Advanced Triple-Negative Breast Carcinoma: NCT06637306 Clinical Landscape Report 2026
15 October 2026
NCT06637306 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Methoxsalen in Non-Small Cell Lung Cancer: NCT06646016 Clinical Landscape Report 2026
15 October 2026
NCT06646016 clinical landscape for Non-Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chidamide in Osteosarcoma: NCT06637007 Clinical Landscape Report 2026
15 October 2026
NCT06637007 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Triple Negative Breast Cancer: NCT06636981 Clinical Landscape Report 2026
15 October 2026
NCT06636981 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DS-2243a in Sarcoma: NCT06644755 Clinical Landscape Report 2026
15 October 2026
NCT06644755 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SG-001 (SineuGene) in Amyotrophic Lateral Sclerosis: NCT06645197 Clinical Landscape Report 2026
15 October 2026
NCT06645197 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VHB937 in Amyotrophic Lateral Sclerosis: NCT06643481 Clinical Landscape Report 2026
15 October 2026
NCT06643481 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tretinoin in High grade B-cell lymphoma: NCT06646666 Clinical Landscape Report 2026
15 October 2026
NCT06646666 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.